FDA record · warning letter

FDA warning letter: Nomida.biz (Sep 12, 2024)

On Sep 12, 2024, FDA issued a warning letter to Nomida.biz under the subject "Unapproved New Drugs/Misbranded". It names semaglutide, tirzepatide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to Nomida.biz
Field	What FDA’s record states	Source
Recipient	Nomida.biz	FDA letter
Location	Not published by FDA	n/a
Letter date	Sep 12, 2024	FDA letter
Posted by FDA	Sep 24, 2024	FDA index
Issuing office	Center for Drug Evaluation and Research (CDER)	FDA letter
Subject	Unapproved New Drugs/Misbranded	FDA letter
MARCS-CMS number	687590	FDA letter
GLP-1 drugs named	Semaglutide, Tirzepatide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“As discussed below, FDA has observed that www.nomida.biz introduces into interstate commerce unapproved and misbranded semaglutide and tirzepatide drug products. There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs.”FDA warning letter to Nomida.biz, Sep 12, 2024 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters